N/A N=364 Development of an Evaluation Method of Elderly Condition in Patient Receiving Chemotherapy Treatment
Lymphoma · Digestive System Diseases · Ovarian Diseases
Primary: Number of Participant Deaths — 56 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=346 Expectations and Priorities of Elderly Patients for a First Medical Treatment for Cancer
Breast Cancer · Colorectal Cancer · Kidney Cancer
Primary: Priorities of Patients Receiving First Medical Treatment for Cancer at Treatment Initiation — 199; 93; 141; 80 Participants
N/A N=450 Access to Care and Prognosis in Elderly With Cancer (INCAPAC Study)
Cancer
Primary: Proportion of Patients Being Receiving Treatment Administration After Diagnosis — 372 Participants
N/A N=546 Improving Communication in Older Cancer Patients and Their Caregivers
Adult Solid Neoplasm · Lymphoma
Primary: Direct Communication About Age-related Concerns: Number of Discussions Related to the Geriatric Assessment That Occur in the Clinic Visit Between the Patient, Oncology…
Phase 2 N=96 Capecitabine Versus S-1 in Elderly Advanced Gastric Cancer (AGC): Randomized Trial
Gastric Cancer
Primary: Response Rate — 28.9; 26.1 percentage of participants
Phase 2 N=62 Pemetrexed/Carboplatin Non-Small Cell Lung Cancer (NSCLC) Elderly Patients
Non Small Cell Lung Cancer
Primary: Percentage of Participants With a Complete or Partial Tumor Response (Overall Tumor Response) — 28.6 percentage of participants
N/A N=14 Assessing Patient-reported & Patient-related Outcomes in Randomized Cancer Trials for Older Adults
Cancer
Primary: Number of Domains Considered Relevant by the Panel of Experts When Assessing Treatment Efficacy in Randomized Cancer Trials for Older Patients With Cancer — 7 geriatric…
N/A N=142 Palliative Care for Elderly Outpatients
Cancer Terminal
Primary: Dignity Impact Scale — 26.3; 26.2; 26.2 score on a scale — p=0.02
N/A N=160 Patient-Centered Care for the Older Adult With Hematologic Malignancy
Hematologic Malignancy
Primary: Overall Survival — 79; 49 Participants
N/A N=733 Geriatric Assessment Intervention for Reducing Toxicity in Older Patients With Advanced Cancer
Adult Solid Neoplasm · Toxicity · Lymphoma
Primary: Patient Experienced Any Grade 3-5 Toxicity — 0.51; 0.71 proportion of participants — p=0.0001
N/A N=16 Geriatric-assessment Interventions to Address Functional Deficits in Older Adults w Multiple Myeloma
Multiple Myeloma · Myeloma · Disability Physical
Primary: Intervention Attendance (Feasibility) — 50 percentage of participants
Phase 2 N=63 The HEALS Project - Health Education and Active Living for Surviving Seniors
Cancer Survivorship · Safety and Efficacy · Quality of Life
Primary: Retention Rates and Class Attendance — 91; 81; 79; 83 percentage of participants
Phase 2 N=83 Pembrolizumab in Elderly Patients With Advanced Lung Cancer
Non Small Cell Lung Cancer
Primary: Overall Survival — 19.2 Months
N/A N=1,606 Emergency Medicine Palliative Care Access
Advanced Cancer · End Stage Organ Failure
Primary: Change in Quality of Life for Patients, as Measured by the Functional Assessment of Cancer Therapy - General (FACT-G) — 3.7; 3.1 score on a scale
N/A N=312 Predicting Severe Toxicity of Targeted Therapies in Elderly Patients With Cancer
Cancer
Primary: Rate of Severe Toxicity — 14; 75; 43 Participants
N/A N=90 Discussing Stopping Cancer Screening and Prognosis With Older Adults
Cancer Screening
Primary: Change in Intentions to be Screened for Colorectal Cancer. — 2.5 score on a scale — p=<0.001
Phase 1 N=18 Study of Postoperative Concurrent Chemo-radiation With Capecitabine in Elderly Rectal Cancer Patients
Rectal Neoplasms
Primary: Dose Related Toxicity — 1; 0; 0; 3 event
N/A N=5,702 Advance Care Planning: Promoting Effective and Aligned Communication in the Elderly
Other Cancer
Primary: Number of Participants With Advance Care Planning Documentation — 0; 1163; 349; 901 Participants — p=<0.05
Phase 2 N=69 Efficacy and Tolerance Evaluation in FOLFIRINOX Dose Adjusted in Elderly Patients With a Metastatic Pancreatic Cancer
Pancreatic Metastatic Cancer · Toxicity
Primary: Composite Safety and Early Efficacy Assessment in the First 34 Patients — 65.8 pourcentage of participants
Phase 2 N=42 Evaluation of Efficacy and Safety of FOLFIRI Association Treatment in Patients 70 Years of Age and Older With Gastric Cancer
Gastric Cancer
Primary: 2-month Response Rate — 25 percentage of participants
Phase 1 N=24 Safety Study of Capecitabine With Radiation in Elderly Rectal Cancer
Rectal Neoplasms
Primary: Number of Participants Experienced Dose Limited Toxicity — 0; 1; 1; 0 participants
N/A N=562 Predictive Analytics and Behavioral Nudges to Improve Palliative Care in Advanced Cancer
Cancer
Primary: Number of Study Participants Who Have Completed a Palliative Care Visit Within 3 Months of Enrollment — 22; 130 participants
Phase 2 N=110 First-Line Treatment of A Comparison of 2 Treatments in Elderly Patients With Advanced NSCLC
Lung Cancer
Primary: Time to Progression (TTP), the Length of Time, in Months, That Patients Were Alive From Their First Date of Protocol Treatment Until Worsening of Their Disease — 4.7…
Phase 2 N=14 Reducing Frailty for Older Cancer Survivors Using Supplements
Frailty · Inflammation
Primary: Recruitment Feasibility: Rates of Consent — 0.375 proportion of participants
N/A N=12 Feasibility of the Memory and Attention Adaptation-Training Geriatrics Intervention in Older Cancer Survivors With Mild Cognitive Impairment
Cognitive Dysfunction
Primary: MAAT-G Feasibility Completion Rate — 10 Participants
N/A N=30 Self-System Therapy for Older Adults With Lung Cancer
Lung Cancer Stage III · Lung Cancer Stage IV
Primary: Number of Patients That Complete SST Treatment Sessions — 23 Participants
N/A N=30 Adaptation of Ca-HELP Intervention in Rural Geriatric Cancer Patient Population
Pain
Primary: Feasibility (Aim 2), as Measured by Number of Subjects Accrued to the Study — 30 Participants
Phase 2 N=67 Diffuse Large B Cell Non-Hodgkin's Lymphoma in the Vulnerable/Frail Elderly. A Multicentric Randomized Phase II Trial
Lymphoma
Primary: Number of Participants in Complete Remission 6 Months After Randomization — 14; 9 Participants
N/A N=1,674 Validation of a Screening Tool in Geriatric Oncology
Breast Cancer · Colorectal Cancer · Head and Neck Cancer
Primary: Sensitivity of the G8 Questionnaire — 76.5 % of Participants with a positive G8
N/A N=42 Geriatric Core Dataset (G-CODE) for Clinical Research in Elderly Cancer Patients
Cancer
Primary: Number of Experts Who Considered That the Question "Do You Live Alone ?" Should be Retained in the G-CODE — 42 Participants